Welcome to our dedicated page for Regenxbio news (Ticker: RGNX), a resource for investors and traders seeking the latest updates and insights on Regenxbio stock.
Regenxbio Inc (RGNX) is a clinical-stage biotechnology leader advancing novel AAV gene therapies through its proprietary NAV® technology platform. This page provides investors and stakeholders with centralized access to the company’s latest press releases, clinical trial updates, and strategic developments.
Track critical updates across Regenxbio’s pipeline, including progress on RGX-202 for Duchenne muscular dystrophy, RGX-121 for Hunter syndrome, and ABBV-RGX-314 for retinal diseases. Stay informed about regulatory milestones, manufacturing advancements, and partnership announcements with entities like AbbVie.
All content is sourced directly from Regenxbio’s official communications, ensuring accuracy and timeliness. Bookmark this page for streamlined access to essential updates on one-time gene therapies targeting rare genetic disorders.
REGENXBIO Inc. (Nasdaq: RGNX) will host a conference call on May 3, 2023, at 4:30 p.m. ET to discuss its financial results for the quarter ending March 31, 2023, along with recent operational highlights. Participants can register for the webcast through the provided links. The company is known for its NAV Technology Platform, which includes over 100 novel AAV vectors and is utilized in developing a variety of therapeutic programs. REGENXBIO aims to achieve its "5x'25" strategy, which targets advancing five AAV therapeutics into pivotal or commercial stages by 2025.
REGENXBIO Inc. (Nasdaq: RGNX) announced it will participate in a fireside chat at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on April 25, 2023, at 9:30 a.m. ET. The conference will occur in a virtual meeting format, with a live webcast accessible via the Investors section of REGENXBIO's website. An archived replay will be available for about 30 days post-event. REGENXBIO focuses on gene therapy, employing its NAV Technology Platform, which includes exclusive rights to over 100 AAV vectors. The company aims to progress five AAV Therapeutics from internal and licensed programs into pivotal or commercial products by 2025.
REGENXBIO announced that the FDA has granted Fast Track designation for RGX-202, a potential one-time gene therapy targeting Duchenne muscular dystrophy. This designation allows faster development and review for therapies addressing serious conditions. RGX-202 utilizes a novel microdystrophin and REGENXBIO's NAV AAV8 vector, aimed at improving muscle resistance. The Phase I/II AFFINITY DUCHENNE trial is currently active, recruiting pediatric patients, with initial data expected in late 2023. The company is leveraging its cGMP facility for clinical supply, reinforcing its commitment to expedite development. RGX-202 has also received Orphan Drug and Rare Pediatric Disease designations from the FDA, highlighting its potential value in addressing unmet medical needs.
FAQ
What is the current stock price of Regenxbio (RGNX)?
What is the market cap of Regenxbio (RGNX)?
